James Hardwick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11571156/publications.pdf Version: 2024-02-01



IAMES HADDWICK

#	Article	IF	CITATIONS
1	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 2015, 21, 449-456.	30.7	1,592
2	Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nature Genetics, 2012, 44, 765-769.	21.4	785
3	Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Research, 2013, 23, 1422-1433.	5.5	457
4	Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nature Communications, 2014, 5, 5477.	12.8	166
5	Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 2129-2140.	1.1	70
6	3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6049-6053.	2.2	44
7	Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5989-5994.	2.2	42
8	Genome-wide identification of RNA editing in hepatocellular carcinoma. Genomics, 2015, 105, 76-82.	2.9	40
9	Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5907-5912.	2.2	34
10	Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6280-6285.	2.2	24
11	Pyridyl aminothiazoles as potent Chk1 inhibitors: Optimization of cellular activity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2613-2619.	2.2	8